Top

Published in:

Open Access 01-10-2020 | Review

Mitochondria, immunosenescence and inflammaging: a role for mitokines?

Authors: Maria Conte, Morena Martucci, Antonio Chiariello, Claudio Franceschi, Stefano Salvioli

Published in: Seminars in Immunopathology | Issue 5/2020

Abstract

A global reshaping of the immune responses occurs with ageing, indicated as immunosenescence, where mitochondria and mitochondrial metabolism play an important role. However, much less is known about the role of mitochondrial stress response in this reshaping and in particular of the molecules induced by such response, collectively indicated as mitokines. In this review, we summarize the current knowledge on the role of mitokines in modulating immune response and inflammation focusing on GDF15, FGF21 and humanin and their possible involvement in the chronic age-related low-grade inflammation dubbed inflammaging. Although many aspects of their biology are still controversial, available data suggest that these mitokines have an anti-inflammatory role and increase with age. Therefore, we hypothesize that they can be considered part of an adaptive and integrated immune-metabolic mechanism activated by mitochondrial dysfunction that acts within the framework of a larger anti-inflammatory network aimed at controlling both acute inflammation and inflammaging.

Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ, Ouslander JG, Weyand CM, Goronzy JJ (2008) T cell subset-specific susceptibility to aging. Clin Immunol 127:107–118. https://doi.org/10.1016/j.clim.2007.12.002CrossRefPubMedPubMedCentral

Cain D, Kondo M, Chen H, Kelsoe G (2009) Effects of acute and chronic inflammation on B-cell development and differentiation. J Invest Dermatol 129:266–277. https://doi.org/10.1038/jid.2008.286CrossRefPubMedPubMedCentral

Condotta SA, Rai D, James BR, Griffith TS, Badovinac VP (2013) Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection. J Immunol 190:1991–2000. https://doi.org/10.4049/jimmunol.1202379CrossRefPubMedPubMedCentral

Shen-Orr SS, Furman D, Kidd BA, Hadad F, Lovelace P, Huang YW et al (2016) Defective signaling in the JAK-STAT pathway tracks with chronic inflammation and cardiovascular risk in aging humans. Cell Syst 3:374–384.e4. https://doi.org/10.1016/j.cels.2016.09.009CrossRefPubMedPubMedCentral

Beyer M, Abdullah Z, Chemnitz JM, Maisel D, Sander J, Lehmann C, Thabet Y, Shinde PV, Schmidleithner L, Köhne M, Trebicka J, Schierwagen R, Hofmann A, Popov A, Lang KS, Oxenius A, Buch T, Kurts C, Heikenwalder M, Fätkenheuer G, Lang PA, Hartmann P, Knolle PA, Schultze JL (2016) Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. Nat Immunol 17:593–603. https://doi.org/10.1038/ni.3399CrossRefPubMed

Hagen M, Derudder E (2020) Inflammation and the alteration of B-cell physiology in aging. Gerontology 66:105–113. https://doi.org/10.1159/000501963CrossRefPubMed

Fulop T, Dupuis G, Baehl S, Le Page A, Bourgade K, Frost E et al (2016) From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology 17:147–157CrossRef

Frasca D, Ferracci F, Diaz A, Romero M, Lechner S, Blomberg BB (2016) Obesity decreases B cell responses in young and elderly individuals. Obesity (Silver Spring) 24:615–625. https://doi.org/10.1002/oby.21383CrossRef

Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G (2008) Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing 5:6. https://doi.org/10.1186/1742-4933-5-6CrossRefPubMedPubMedCentral

10.

McElhaney JE, Effros RB (2009) Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 21:418–424. https://doi.org/10.1016/j.coi.2009.05.023CrossRefPubMedPubMedCentral

11.

Haralambieva IH, Painter SD, Kennedy RB, Ovsyannikova IG, Lambert ND, Goergen KM, Oberg AL, Poland GA (2015) The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PLoSOne 10:e0122282. https://doi.org/10.1371/journal.pone.0122282CrossRef

12.

Briceño O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, Miquel T, Gostick E, Papagno L, Stiasny K, Price DA, Mallone R, Sauce D, Karrer U, Appay V (2016) Reduced naïve CD8(+) T-cell priming efficacy in elderly adults. Aging Cell 15:14–21. https://doi.org/10.1111/acel.12384CrossRefPubMed

13.

Kennedy RB, Simon WL, Gibson MJ, Goergen KM, Grill DE, Oberg AL, Poland GA (2016) The composition of immune cells serves as a predictor of adaptive immunity in a cohort of 50- to 74-year-old adults. Immunology 148:266–275. https://doi.org/10.1111/imm.12599CrossRefPubMedPubMedCentral

14.

Parmigiani A, Alcaide ML, Freguja R, Pallikkuth S, Frasca D, Fischl MA, Pahwa S (2013) Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One 8:e79816. https://doi.org/10.1371/journal.pone.0079816CrossRefPubMedPubMedCentral

15.

Frasca D, Romero M, Diaz A, Alter-Wolf S, Ratliff M, Landin AM, Riley RL, Blomberg BB (2012) A molecular mechanism for TNF-alpha-mediated downregulation of B cell responses. J Immunol 188:279–286. https://doi.org/10.4049/jimmunol.1003964CrossRefPubMed

16.

Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB (2014) High TNF-α levels in resting B cells negatively correlate with their response. Exp Gerontol 54:116–122. https://doi.org/10.1016/j.exger.2014.01.004CrossRefPubMed

17.

Roquilly A, Jacqueline C, Davieau M, Mollé A, Sadek A, Fourgeux C, Rooze P, Broquet A, Misme-Aucouturier B, Chaumette T, Vourc’h M, Cinotti R, Marec N, Gauttier V, McWilliam HEG, Altare F, Poschmann J, Villadangos JA, Asehnoune K (2020) Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. Nat Immunol 21:636–648. https://doi.org/10.1038/s41590-020-0673-xCrossRefPubMed

18.

Jensen IJ, Winborn CS, Fosdick MG, Shao P, Tremblay MM, Shan Q, Tripathy SK, Snyder CM, Xue HH, Griffith TS, Houtman JC, Badovinac VP (2018) Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections. PLoS Pathog 14:e1007405. https://doi.org/10.1371/journal.ppat.1007405CrossRefPubMedPubMedCentral

19.

Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E, Apte RN (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J Immunol 175:8200–8208. https://doi.org/10.4049/jimmunol.175.12.8200CrossRefPubMed

20.

Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507–4513. https://doi.org/10.1158/0008-5472.CAN-06-4174CrossRefPubMed

21.

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019–10026. https://doi.org/10.1158/0008-5472.CAN-07-2354CrossRefPubMedPubMedCentral

22.

Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E et al (2000) Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244–254. Review. https://doi.org/10.1111/j.1749-6632.2000.tb06651.xCrossRefPubMed

23.

McGuire PJ (2019) Mitochondrial dysfunction and the aging immune system. Biology (Basel) 8:E26. https://doi.org/10.3390/biology8020026CrossRef

24.

Riley JS, Tait SWG (2020) Mitochondrial DNA in inflammation and immunity. EMBO Rep:e49799. https://doi.org/10.15252/embr.201949799

25.

Laskin DL (2009) Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol 22:1376–1385. https://doi.org/10.1021/tx900086vCrossRefPubMedPubMedCentral

26.

Davis BK, Wen H, Ting JP (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29:707–735. https://doi.org/10.1146/annurev-immunol-031210-101405CrossRefPubMedPubMedCentral

27.

Arango Duque G, Descoteaux A (2014) Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 5:491. https://doi.org/10.3389/fimmu.2014.00491CrossRefPubMedPubMedCentral

28.

Turner MD, Nedjai B, Hurst T, Pennington DJ (2014) Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta 1843:2563–2582. https://doi.org/10.1016/j.bbamcr.2014.05.014CrossRefPubMed

29.

Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S (2017) Inflammaging and 'Garb-aging'. Trends Endocrinol Metab 28:199–212. https://doi.org/10.1016/j.tem.2016.09.005CrossRefPubMed

30.

Pinti M, Cevenini E, Nasi M, De Biasi S, Salvioli S, Monti D et al (2014) Circulating mitochondrial DNA increases with age and is a familiar trait: implications for "inflamm-aging". Eur J Immunol 44:1552–1562. https://doi.org/10.1002/eji.201343921CrossRefPubMed

31.

Tarasenko T, Pacheco SE, Koenig MK, Gomez-Rodriguez J, Kapnick SM, Diaz F et al (2017) Cytochrome c oxidase activity is a metabolic checkpoint that regulates cell fate decisions during T cell activation and differentiation. Cell Metab 25:1256–1268 e1257. https://doi.org/10.1016/j.cmet.2017.05.007CrossRef

32.

Bailis W, Shyer JA, Zhao J, Canaveras JCG, Al Khazal FJ, Qu R et al (2019) Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. Nature 571:403–407. https://doi.org/10.1038/s41586-019-1311-3CrossRefPubMedPubMedCentral

33.

Bektas A, Schurman SH, Gonzalez-Freire M, Dunn CA, Singh AK, Macian F et al (2019) Age-associated changes in human CD4(+) T cells point to mitochondrial dysfunction consequent to impaired autophagy. Aging (Albany NY) 11:9234–9263. https://doi.org/10.18632/aging.102438CrossRef

34.

Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers ES, Subramanian P, Patel N, Virasami A, Sebire NJ, Kinsler V, Valdovinos A, LeSaux CJ, Passos JF, Antoniou A, Rustin MHA, Campisi J, Akbar AN (2019) Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition. Nat Commun 10:2387. https://doi.org/10.1038/s41467-019-10335-5CrossRefPubMedPubMedCentral

35.

Callender LA, Carroll EC, Bober EA, Akbar AN, Solito E, Henson SM (2020) Mitochondrial mass governs the extent of human T cell senescence. Aging Cell 19:e13067. https://doi.org/10.1111/acel.13067CrossRefPubMed

36.

Waters LR, Ahsan FM, Wolf DM, Shirihai O, Teitell MA (2018) Initial B cell activation induces metabolic reprogramming and mitochondrial remodeling. iScience 5:99–109. https://doi.org/10.1016/j.isci.2018.07.005CrossRefPubMedPubMedCentral

37.

Heyse S, Connolly T, Chiles T (2015) The regulation and role of L-glutamine in B-cell activation. FASEB J 29:888.17

38.

Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ, Weissman IL (2005) Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 102:9194–9199. https://doi.org/10.1073/pnas.0503280102CrossRefPubMedPubMedCentral

39.

Kretzschmar C, Roolf C, Timmer K, Sekora A, Knübel G, Escobar HM et al (2016) Uncoupling protein 2 deficiency results in higher neutrophil counts and lower B-cell counts during aging in mice. Exp Hematol 44:1085–1091.e2. https://doi.org/10.1016/j.exphem.2016.08.003CrossRefPubMed

40.

Rose G, Santoro A, Salvioli S (2017) Mitochondria and mitochondria-induced signalling molecules as longevity determinants. Mech Ageing Dev 165(Pt B):115–128. https://doi.org/10.1016/j.mad.2016.12.002CrossRefPubMed

41.

Rea SL, Ventura N, Johnson TE (2007) Relationship between mitochondrial electron transport chain dysfunction, development, and life extension in Caenorhabditis elegans. PLoS Biol 5:e259CrossRef

42.

Yao RQ, Ren C, Xia ZF, Yao YM (2020) Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. Autophagy 12:1–17. https://doi.org/10.1080/15548627.2020.1725377CrossRef

43.

Ji T, Zhang X, Xin Z, Xu B, Jin Z, Wu J, Hu W, Yang Y (2020) Does perturbation in the mitochondrial protein folding pave the way for neurodegeneration diseases? Ageing Res Rev 57:100997. https://doi.org/10.1016/j.arr.2019.100997CrossRefPubMed

44.

Durieux J, Wolff S, Dillin A (2011) The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 144:79–91. https://doi.org/10.1016/j.cell.2010.12.016CrossRefPubMedPubMedCentral

45.

Shao LW, Niu R, Liu Y (2016) Neuropeptide signals cell non-autonomous mitochondrial unfolded protein response. Cell Res 26:1182–1196. https://doi.org/10.1038/cr.2016.118CrossRefPubMedPubMedCentral

46.

Kim KH, Jeong YT, Kim SH, Jung HS, Park KS, Lee HY, Lee MS (2013a) Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. Biochem Biophys Res Commun 440:76–81. https://doi.org/10.1016/j.bbrc.2013.09.026CrossRefPubMed

47.

Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, Kim YN, Kim SS, Kim DH, Hur KY, Kim HK, Ko TH, Han J, Kim HL, Kim J, Back SH, Komatsu M, Chen H, Chan DC, Konishi M, Itoh N, Choi CS, Lee MS (2013b) Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 19:83–92. https://doi.org/10.1038/nm.3014CrossRefPubMed

48.

Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, Sue CM (2013) Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology. 81:1819–1826. https://doi.org/10.1212/01.wnl.0000436068.43384.efCrossRefPubMed

49.

Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, Kojima T, Ito M, Tanaka M, Saiki R, Koga Y (2015) Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol 78:814–823. https://doi.org/10.1002/ana.24506CrossRefPubMedPubMedCentral

50.

Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, Ito M (2016) Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int 1:17–29. https://doi.org/10.1111/ggi.12724CrossRef

51.

Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, Kita Y, Kawasumi M, Kouyama K, Doyu M, Sobue G, Koide T, Tsuji S, Lang J, Kurokawa K, Nishimoto I (2001) A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A 98(11):6336–6341CrossRef

52.

Zarse K, Ristow M (2015) A mitochondrially encoded hormone ameliorates obesity and insulin resistance. Cell Metab 21:355–356. https://doi.org/10.1016/j.cmet.2015.02.013CrossRefPubMed

53.

Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P (2015) The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 21:443–454. https://doi.org/10.1016/j.cmet.2015.02.009CrossRefPubMedPubMedCentral

54.

Cobb LJ, Lee C, Xiao J, Yen K, Wong RG, Nakamura HK et al (2016) Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging 8:796–809. https://doi.org/10.18632/aging.100943CrossRefPubMedPubMedCentral

55.

Conte M, Ostan R, Fabbri C, Santoro A, Guidarelli G, Vitale G, Mari D, Sevini F, Capri M, Sandri M, Monti D, Franceschi C, Salvioli S (2019) Human aging and longevity are characterized by high levels of mitokines. J Gerontol A Biol Sci Med Sci 74:600–607. https://doi.org/10.1093/gerona/gly153CrossRefPubMed

56.

Tanaka T, Biancotto A, Moaddel R, Moore AZ, Gonzalez-Freire M, Aon MA, Candia J, Zhang P, Cheung F, Fantoni G, CHI consortium, Semba RD, Ferrucci L (2018) Plasma proteomic signature of age in healthy humans. Aging Cell 17:e12799. https://doi.org/10.1111/acel.12799CrossRefPubMedPubMedCentral

57.

Lehallier B, Gate D, Schaum N, Nanasi T, Lee SE, Yousef H, Moran Losada P, Berdnik D, Keller A, Verghese J, Sathyan S, Franceschi C, Milman S, Barzilai N, Wyss-Coray T (2019) Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 25:1843–1850. https://doi.org/10.1038/s41591-019-0673-2CrossRefPubMedPubMedCentral

58.

Corre J, Hébraud B, Bourin P (2013) Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med 2:946–952. https://doi.org/10.5966/sctm.2013-0055CrossRefPubMedPubMedCentral

59.

Adela R, Banerjee SK (2015) GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res 2015:490842–490814. https://doi.org/10.1155/2015/490842CrossRefPubMedPubMedCentral

60.

Fujita Y, Ito M, Kojima T, Yatsuga S, Koga Y, Tanaka M (2015) GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion 20:34–42. https://doi.org/10.1016/j.mito.2014.10.006CrossRefPubMed

61.

Liu JJ, Foo JP, Liu S, Lim SC (2015) The role of fibroblast growth factor 21 in diabetes and its complications: a review from clinical perspective. Diabetes Res Clin Pract 108:382–389. https://doi.org/10.1016/j.diabres.2015.02.032CrossRefPubMed

62.

Salminen A, Kaarniranta K, Kauppinen A (2017) Regulation of longevity by FGF21: interaction between energy metabolism and stress responses. Ageing Res Rev 37:79–93. https://doi.org/10.1016/j.arr.2017.05.004CrossRefPubMed

63.

Xie T, Leung PS (2017) Fibroblast growth factor 21: a regulator of metabolic disease and health span. Am J Physiol Endocrinol Metab 313:E292–E302. https://doi.org/10.1152/ajpendo.00101.2017CrossRefPubMedPubMedCentral

64.

Tezze C, Romanello V, Desbats MA, Fadini GP, Albiero M, Favaro G et al (2017) Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab 25:1374–1389.e6. https://doi.org/10.1016/j.cmet.2017.04.021CrossRefPubMedPubMedCentral

65.

Thummasorn S, Shinlapawittayatorn K, Khamseekaew J, Jaiwongkam T, Chattipakorn SC, Chattipakorn N (2018) Humanin directly protects cardiac mitochondria against dysfunction initiated by oxidative stress by decreasing complex I activity. Mitochondrion 38:31–40. https://doi.org/10.1016/j.mito.2017.08.001CrossRefPubMed

66.

Ristow M, Zarse K (2010) How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp Gerontol 45:410–418. https://doi.org/10.1016/j.exger.2010.03.014CrossRefPubMed

67.

Klaus S, Ost M (2020) Mitochondrial uncoupling and longevity - a role for mitokines? Exp Gerontol 130:110796. https://doi.org/10.1016/j.exger.2019.110796CrossRefPubMed

68.

Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342–350CrossRef

69.

Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17:581–588CrossRef

70.

Kalli M, Minia A, Pliaka V, Fotis C, Alexopoulos LG, Stylianopoulos T (2019) Solid stress-induced migration is mediated by GDF15 through Akt pathway activation in pancreatic cancer cells. Sci Rep 9:978. https://doi.org/10.1038/s41598-018-37425-6CrossRefPubMedPubMedCentral

71.

Tarfiei GA, Shadboorestan A, Montazeri H, Rahmanian N, Tavosi G, Ghahremani MH (2019) GDF15 induced apoptosis and cytotoxicity in A549 cells depends on TGFBR2 expression. Cell Biochem Funct 37:320–330. https://doi.org/10.1002/cbf.3391CrossRefPubMed

72.

Chung HK, Kim JT, Kim HW, Kwon M, Kim SY, Shong M, Kim KS, Yi HS (2017) GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury. Sci Rep 7:17238CrossRef

73.

Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94:11514–11519CrossRef

74.

Tan M, Wang Y, Guan K, Sun Y (2000) PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 97:109–114. https://doi.org/10.1073/pnas.97.1.109CrossRefPubMedPubMedCentral

75.

Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM et al (2019) GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell 178:1231–1244.e11CrossRef

76.

Conte M, Martucci M, Mosconi G, Chiariello A, Cappuccilli M, Totti V, Santoro A, Franceschi C, Salvioli S (2020) GDF15 plasma level is inversely associated with level of physical activity and correlates with markers of inflammation and muscle weakness. Front Immunol 11:915. https://doi.org/10.3389/fimmu.2020.00915CrossRefPubMedPubMedCentral

77.

Freeman CM, Martinez CH, Todt JC, Martinez FJ, Han MK, Thompson DL et al (2015) Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respir Res 16:94. https://doi.org/10.1186/s12931-015-0251-1CrossRefPubMedPubMedCentral

78.

de Jager SC, Bermúdez B, Bot I, Koenen RR, Bot M, Kavelaars A et al (2011) Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med 208:217–225. https://doi.org/10.1084/jem.20100370CrossRefPubMedPubMedCentral

79.

Bonaterra GA, Zügel S, Thogersen J, Walter SA, Haberkorn U, Strelau J, Kinscherf R (2012) Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury. J Am Heart Assoc 1:e002550. https://doi.org/10.1161/JAHA.112.002550CrossRefPubMedPubMedCentral

80.

Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, Kuffner T et al (2011) The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29:187–195. https://doi.org/10.3109/08977194.2011.607137CrossRefPubMed

81.

Lerner L, Tao J, Liu Q, Nicoletti R, Feng B, Krieger B, Mazsa E, Siddiquee Z, Wang R, Huang L, Shen L, Lin J, Vigano A, Chiu MI, Weng Z, Winston W, Weiler S, Gyuris J (2016) MAP3K11/GDF15 axis is a critical driver of cancer cachexia. J Cachexia Sarcopenia Muscle 7:467–482. https://doi.org/10.1002/jcsm.12077CrossRefPubMed

82.

Tsai VW, Brown DA, Breit SN (2018) Targeting the divergent TGFβ superfamily cytokine MIC-1/GDF15 for therapy of anorexia/cachexia syndromes. Curr Opin Support Palliat Care 12:404–409. https://doi.org/10.1097/SPC.0000000000000384CrossRefPubMed

83.

Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L et al (2010) Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 9:1057–1064. https://doi.org/10.1111/j.1474-9726.2010.00629.xCrossRefPubMedPubMedCentral

84.

Wollert KC, Kempf T, Wallentin L (2017) Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 63:140–151. https://doi.org/10.1373/clinchem.2016.255174CrossRefPubMed

85.

Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkjær SB, Wu X, Huang T, Hultman K, Paulsen SJ, Wang J, Bugge A, Frantzen JB, Nørgaard P, Jeppesen JF, Yang Z, Secher A, Chen H, Li X, John LM, Shan B, He Z, Gao X, Su J, Hansen KT, Yang W, Jørgensen SB (2017) GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 23:1158–1166. https://doi.org/10.1038/nm.4394CrossRefPubMed

86.

Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Cash-Mason TD, Cavanaugh CR, Nelson S, Huang C, Hunter MJ, Rangwala SM (2017) GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 23:1150–1157. https://doi.org/10.1038/nm.4392CrossRefPubMed

87.

Lee DH, Yang Y, Lee SJ, Kim K, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648–4655PubMed

88.

Codó P, Weller M, Kaulich K, Schraivogel D, Silginer M, Reifenberger G et al (2016) Control of glioma cell migration and invasiveness by GDF-15. Oncotarget 7:7732–7746. https://doi.org/10.18632/oncotarget.6816CrossRefPubMedPubMedCentral

89.

Min KW, Liggett JL, Silva G, Wang R, Shen R, Eling TE et al (2016) NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway. Oncogene 35:377–388. https://doi.org/10.1038/onc.2015.95CrossRefPubMed

90.

Lu Y, Ma J, Li Y, Huang J, Zhang S, Yin Z, Ren J, Huang K, Wu G, Yang K, Xu S (2017) CDP138 silencing inhibits TGF-β/Smad signaling to impair radioresistance and metastasis via GDF15 in lung cancer. Cell Death Dis 8:e3036. https://doi.org/10.1038/cddis.2017.434CrossRefPubMedPubMedCentral

91.

Olsen OE, Skjærvik A, Størdal BF, Sundan A, Holien T (2017) TGF-β contamination of purified recombinant GDF15. PLoS One 12:e0187349. https://doi.org/10.1371/journal.pone.0187349CrossRefPubMedPubMedCentral

92.

Hashimoto Y, Kurita M, Aiso S, Nishimoto I, Matsuoka M (2009) Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Mol Biol Cell 20:2864–2873. https://doi.org/10.1091/mbc.E09-02-0168CrossRefPubMedPubMedCentral

93.

Zhang X, Urbieta-Caceres VH, Eirin A, Bell CC, Crane JA, Tang H, Jordan KL, Oh YK, Zhu XY, Korsmo MJ, Bachar AR, Cohen P, Lerman A, Lerman LO (2012) Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient mice. Life Sci 91:199–206. https://doi.org/10.1016/j.lfs.2012.07.010CrossRefPubMedPubMedCentral

94.

Zhao ST, Zhao L, Li JH (2013) Neuroprotective peptide humanin inhibits inflammatory response in astrocytes induced by lipopolysaccharide. Neurochem Res 38:581–588. https://doi.org/10.1007/s11064-012-0951-6CrossRefPubMed

95.

Gottardo MF, Jaita G, Magri ML, Zárate S, Ayala MM, Ferraris J et al (2014) Antiapoptotic factor humanin is expressed in normal and tumoral pituitary cells and protects them from TNF-α-induced apoptosis. PLoS One 9:e111548. https://doi.org/10.1371/jpuornal.pone.0111548CrossRefPubMedPubMedCentral

96.

Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, Nishimoto I, Cohen P (2003) Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci U S A 100:13042–13047CrossRef

97.

Rensink AA, Gellekink H, Otte-Höller I, ten Donkelaar HJ, de Waal RM, Verbeek MM, Kremer B (2002) Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease. Acta Neuropathol 104:525–533CrossRef

98.

Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, Reed JC (2003) Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423:456–461CrossRef

99.

Zacharias DG, Kim SG, Massat AE, Bachar AR, Oh YK, Herrmann J, Rodriguez-Porcel M, Cohen P, Lerman LO, Lerman A (2012) Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans. PLoS One 7:e31065. https://doi.org/10.1371/journal.pone.0031065CrossRefPubMedPubMedCentral

100.

Kuliawat R, Klein L, Gong Z, Nicoletta-Gentile M, Nemkal A, Cui L, Bastie C, Su K, Huffman D, Surana M, Barzilai N, Fleischer N, Muzumdar R (2013) Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the β cell. FASEB J 27:4890–4898. https://doi.org/10.1096/fj.13-231092CrossRefPubMedPubMedCentral

101.

Thummasorn S, Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N (2017) High-dose humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction. Cardiovasc Ther:35. https://doi.org/10.1111/1755-5922.12289

102.

Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A (2018) (2018a) Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 14(10):576–590. https://doi.org/10.1038/s41574-018-0059-4CrossRefPubMed

103.

Franceschi C, Garagnani P, Morsiani C, Conte M, Santoro A, Grignolio A, Monti D, Capri M, Salvioli S (2018b) The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med (Lausanne) 5:61. https://doi.org/10.3389/fmed.2018.00061CrossRef

104.

Yen K, Mehta HH, Kim SJ, Lue Y, Hoang J, Guerrero N et al (2020) The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY) 12:10.18632/aging.103534

105.

Salemi M, Ridolfo F, Salluzzo MG, Cannarrella R, Giambirtone M, Caniglia S, Tirolo C, Ferri R, Romano C (2020) Humanin gene expression in fibroblast of Down syndrome subjects. Int J Med Sci 17:320–324. https://doi.org/10.7150/ijms.39145CrossRefPubMedPubMedCentral

106.

Ji K, Zheng J, Lv J, Xu J, Ji X, Luo YB, Li W, Zhao Y, Yan C (2015) Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1α pathway. Free Radic Biol Med 84:161–170. https://doi.org/10.1016/j.freeradbiomed.2015.03.020CrossRefPubMed

107.

Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Satjaritanun P, Wang X, Liang G et al (2016) FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats. Horm Behav 85:86–95. https://doi.org/10.1016/j.yhbeh.2016.08.006CrossRefPubMed

108.

Restelli LM, Oettinghaus B, Halliday M, Agca C, Licci M, Sironi L, Savoia C, Hench J, Tolnay M, Neutzner A, Schmidt A, Eckert A, Mallucci G, Scorrano L, Frank S (2018) Neuronal mitochondrial dysfunction activates the integrated stress response to induce fibroblast growth factor 21. Cell Rep 2018;24(6):1407–1414. doi: https://doi.org/10.1016/j.celrep.2018.07.023

109.

Yu Y, He J, Li S, Song L, Guo X, Yao W, Zou D, Gao X, Liu Y, Bai F, Ren G, Li D (2016) Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol 38:144–152. https://doi.org/10.1016/j.intimp.2016.05.026CrossRefPubMed

110.

Gao J, Liu Q, Li J, Hu C, Zhao W, Ma W, Yao M, Xing L (2020) Fibroblast growth factor 21 dependent TLR4/MYD88/NF-κB signaling activation is involved in lipopolysaccharide-induced acute lung injury. Int Immunopharmacol 80:106219. https://doi.org/10.1016/j.intimp.2020.106219CrossRefPubMed

111.

Jia H, Cheng J, Zhou Q, Peng J, Pan Y, Han H (2018) Fibroblast growth factor 21 attenuates inflammation and oxidative stress in atherosclerotic rat via enhancing the Nrf1-ARE signaling pathway. Int J Clin Exp Pathol 11:1308–1317PubMedPubMedCentral

112.

Youm YH, Horvath TL, Mangelsdorf DJ, Kliewer SA, Dixit VD (2016) Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. Proc Natl Acad Sci U S A 113:1026–1031. https://doi.org/10.1073/pnas.1514511113CrossRefPubMedPubMedCentral

113.

Sanchis-Gomar F, Pareja-Galeano H, Santos-Lozano A, Garatachea N, Fiuza-Luces C, Venturini L, Ricevuti G, Lucia A, Emanuele E (2015) A preliminary candidate approach identifies the combination of chemerin, fetuin-A, and fibroblast growth factors 19 and 21 as a potential biomarker panel of successful aging. Age (Dordr) 37:9776. https://doi.org/10.1007/s11357-015-9776-yCrossRef

114.

Rath E, Berger E, Messlik A, Nunes T, Liu B, Kim SC, Hoogenraad N, Sans M, Sartor RB, Haller D (2012) Induction of dsRNA-activated protein kinase links mitochondrial unfolded protein response to the pathogenesis of intestinal inflammation. Gut 61:1269–1278. https://doi.org/10.1136/gutjnl-2011-300767CrossRefPubMed

115.

Pellegrino MW, Nargund AM, Kirienko NV, Gillis R, Fiorese CJ, Haynes CM (2014) Mitochondrial UPR-regulated innate immunity provides resistance to pathogen infection. Nature 516:414–417. https://doi.org/10.1038/nature13818CrossRefPubMedPubMedCentral

116.

Lin YF, Haynes CM (2016) Metabolism and the UPR(mt). Mol Cell 61:677–682. https://doi.org/10.1016/j.molcel.2016.02.004CrossRefPubMedPubMedCentral

117.

Martinez BA, Petersen DA, Gaeta AL, Stanley SP, Caldwell GA, Caldwell KA (2017) Dysregulation of the mitochondrial unfolded protein response induces non-apoptotic dopaminergic neurodegeneration in C. elegans models of Parkinson's disease. J Neurosci 37:11085–11100. https://doi.org/10.1523/JNEUROSCI.1294-17.2017CrossRefPubMedPubMedCentral

118.

Lu H, Tang S, Xue C, Liu Y, Wang J, Zhang W et al (2019) Mitochondrial-derived peptide MOTS-c increases adipose thermogenic activation to promote cold adaptation. Int J Mol Sci 20:E2456. https://doi.org/10.3390/ijms20102456CrossRefPubMed

119.

Kim SJ, Mehta HH, Wan J, Kuehnemann C, Chen J, Hu JF et al (2018) Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY) 10(6):1239–1256. https://doi.org/10.18632/aging.101463CrossRef

120.

Zhai D, Ye Z, Jiang Y, Xu C, Ruan B, Yang Y, Lei X, Xiang A, Lu H, Zhu Z, Yan Z, Wei D, Li Q, Wang L, Lu Z (2017) MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol Immunol 92:151–160. https://doi.org/10.1016/j.molimm.2017.10.017CrossRefPubMed

121.

Yan Z, Zhu S, Wang H, Wang L, Du T, Ye Z et al (2019) MOTS-c inhibits osteolysis in the mouse calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation. Pharmacol Res 147:104381. https://doi.org/10.1016/j.phrs.2019.104381CrossRefPubMed

122.

Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Hirose N (2015) The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell 14:921–923. https://doi.org/10.1111/acel.12389CrossRefPubMedPubMedCentral

123.

Nashine S, Cohen P, Nesburn AB, Kuppermann BD, Kenney MC (2018) Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration. Sci Rep 8:15175. https://doi.org/10.1038/s41598-018-33290-5CrossRefPubMedPubMedCentral

124.

Mehta HH, Xiao J, Ramirez R, Miller B, Kim SJ, Cohen P, Yen K (2019) Metabolomic profile of diet induced obesity mice in response to humanin and small humanin-like peptide 2 treatment. Metabolomics 15:88. https://doi.org/10.1007/s11306-019-1549-7CrossRefPubMedPubMedCentral

125.

Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128:92–105CrossRef

126.

Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafè M, Cavallone L, Franceschi C, Caruso C (2002) Gender-specific association between −1082 IL-10 promoter polymorphism and longevity. Genes Immun 3:30–33CrossRef

127.

Bucci L, Ostan R, Cevenini E, Pini E, Scurti M, Vitale G, Mari D, Caruso C, Sansoni P, Fanelli F, Pasquali R, Gueresi P, Franceschi C, Monti D (2016) Centenarians' offspring as a model of healthy aging: a reappraisal of the data on Italian subjects and a comprehensive overview. Aging (Albany NY) 8:510–519CrossRef

128.

Storci G, De Carolis S, Papi A, Bacalini MG, Gensous N, Marasco E et al (2019) Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNAseH2 in cells from centenarians. Cell Death Differ 26:1845–1858. https://doi.org/10.1038/s41418-018-0255-8CrossRefPubMedPubMedCentral

Title: Mitochondria, immunosenescence and inflammaging: a role for mitokines?
Authors: Maria Conte
Morena Martucci
Antonio Chiariello
Claudio Franceschi
Stefano Salvioli
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Published in: Seminars in Immunopathology / Issue 5/2020
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-020-00813-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Microbiomes other than the gut: inflammaging and age-related diseases

Adipose tissue, immune aging, and cellular senescence

Immunosenescence is both functional/adaptive and dysfunctional/maladaptive

The interplay between immunosenescence and age-related diseases

The human immunosenescence phenotype: does it exist?

Down syndrome, accelerated aging and immunosenescence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage